NCT05635929 2026-04-15
STOPOMP
Mucosa Innovations, S.L.
Phase NA Recruiting
Clinical Trials
29 trialsNCT04651634 2025-04-06
MIT-001
MitoImmune Therapeutics
Phase 2 Active not recruiting
NCT05966194 2024-11-15
KEVLARx
EpicentRx, Inc.
Phase 2 Recruiting
NCT03515538 2024-11-04
PREVLAR
EpicentRx, Inc.
Phase 2 Completed
NCT03972527 2024-08-21
Photobiomodulation to Demonstrate Safety and Reduce the Incidence of Oral Mucositis in Adult Head & Neck Cancer Patients
MuReva Phototherapy Inc.
Phase NA Completed
NCT03689712 2023-10-24
ROMAN: Phase 3 Trial Investigating the Effects of GC4419 on Radiation Induced Oral Mucositis in Head/Neck Cancer Patients
Galera Therapeutics, Inc.
Phase 3 Completed
NCT05994638 2023-10-13
Polyphenol Rich Aerosol as a Support for Cancer Patients in Minimizing Side Effects After a Radiation Therapy
AronPharma Sp. z o. o.
Phase NA Unknown
NCT04648020 2023-05-31
VOICE
Monopar Therapeutics
Phase 2/3 Terminated
NCT05055726 2022-11-16
BOOM
Aziende Chimiche Riunite Angelini Francesco S.p.A
Phase 4 Completed
NCT03237325 2022-11-08
DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer
Soligenix
Phase 3 Completed
NCT04699487 2022-10-10
PrOMiSE
NeoMedLight
Phase NA Completed
NCT04529850 2022-08-16
Ph 2 Open Label Study of GC4419 to Reduce SOM Associated With Chemoradiotherapy for Head and Neck Cancer
Galera Therapeutics, Inc.
Phase 2 Completed
NCT02399228 2021-11-19
A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of Oral Mucositis
Santalis Pharmaceuticals, Inc.
Phase 2 Completed
NCT02508389 2021-09-20
A Study of the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer
Galera Therapeutics, Inc.
Phase 2 Completed
NCT01403064 2021-05-11
Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects
CSL Behring
Phase 2 Terminated
NCT03988556 2021-04-30
SafePBM
NeoMedLight
Phase NA Completed
NCT02324335 2019-01-16
Brilacidin
Innovation Pharmaceuticals, Inc.
Phase 2 Completed
NCT01400620 2018-03-13
Safety and Efficacy of IZN-6N4 Oral Rinse for the Prevention of Oral Mucositis in Patients With Head and Neck Cancer
Izun Pharma Ltd
Phase 2 Completed
NCT02630004 2018-03-01
MUCOMEL
Spherium Biomed
Phase 1/2 Completed
NCT00131638 2016-12-16
A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer
Amgen
Phase 3 Completed
NCT00101582 2016-09-27
Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer
Swedish Orphan Biovitrum
Phase 3 Completed
NCT01921426 2016-09-22
A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck
Galera Therapeutics, Inc.
Phase 1 Completed
NCT01247246 2014-05-26
Study to Evaluate the Efficacy and Safety of Three Different Doses of SCV 07 in Attenuating Oral Mucositis in Subjects With Head and Neck Cancer
SciClone Pharmaceuticals
Phase 2 Unknown
NCT00574860 2013-09-20
EN3285 for the Prevention or Delay of Oral Mucositis in Patients With Head and Neck Cancer
Endo Pharmaceuticals
Phase 3 Terminated
NCT01283906 2013-09-12
MuGard
Access Pharmaceuticals, Inc.
Phase 4 Completed
NCT00790322 2010-02-19
Efficacy and Safety Study of SBG vs Placebo in Head and Neck Cancer Patients Undergoing Radiation Therapy
Biotec Pharmacon ASA
Phase 3 Completed
NCT00756951 2009-11-23
SCV-07 OM
SciClone Pharmaceuticals
Phase 2 Completed
NCT00540332 2009-03-02
A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy
Swedish Orphan Biovitrum
Phase 1/2 Withdrawn
NCT00230191 2007-01-15
Safety and Efficacy of RK0202 in Oral Mucositis
RxKinetix
Phase 2 Completed